Amedeo Smart

Free Medical Literature Service



Multiple Sclerosis

  Free Subscription

Articles published in
J Neurol Sci
    March 2024
  1. CHAER LER, de Mendonca JM, Del Negro MC, Titze-de-Almeida R, et al
    Differential diagnosis between multiple sclerosis and leukodystrophies - A scoping review.
    J Neurol Sci. 2024;459:122969.
    >> Share

  2. BERNARDES C, Fernandes C, Cunha C, Nunes C, et al
    Natalizumab extended interval dosing: what about wearing-off effect?
    J Neurol Sci. 2024;458:122930.
    >> Share

    February 2024
  3. RECHTMAN A, Zveik O, Haham N, Freidman-Korn T, et al
    Thyroid hormone dysfunction in MOGAD and other demyelinating diseases.
    J Neurol Sci. 2024;457:122866.
    >> Share

  4. BALCOM EF, Smyth P, Kate M, Vu K, et al
    Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
    J Neurol Sci. 2024;458:122913.
    >> Share

  5. KUSNIRIKOVA ZK, Kacirova I, Pesakova V, Hradilek P, et al
    Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    J Neurol Sci. 2024;458:122910.
    >> Share

    January 2024
  6. ZANETTA C, Faustino P, Guerrieri S, Nozzolillo A, et al
    Fast but not furious: Rapid ocrelizumab infusion as a strategy to optimize multiple sclerosis patients' management.
    J Neurol Sci. 2024;457:122897.
    >> Share

  7. MOTEGI H, Kufukihara K, Kitagawa S, Sekiguchi K, et al
    Non-lesional white matter changes depicted by q-space diffusional MRI correlate with clinical disabilities in multiple sclerosis.
    J Neurol Sci. 2024;456:122851.
    >> Share

  8. HJAERESEN S, Benedikz E, Sejbaek T, Axelsson M, et al
    High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    J Neurol Sci. 2024;457:122888.
    >> Share

  9. RAGHIB MF, Bao F, Elkhooly M, Bernitsas E, et al
    Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2024;457:122884.
    >> Share

    December 2023
  10. KREITER D, Postma AA, Hupperts R, Gerlach O, et al
    Hallmarks of spinal cord pathology in multiple sclerosis.
    J Neurol Sci. 2023;456:122846.
    >> Share

  11. MARANTOS T, Kyriazopoulou E, Lekakis V, Voumvourakis KI, et al
    Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2023;456:122852.
    >> Share

  12. DOHERTY F, Powell P, McBride C, Monaghan K, et al
    Physical Telerehabilitation interventions for Gait and balance in Multiple sclerosis: A Scoping review.
    J Neurol Sci. 2023;456:122827.
    >> Share

    November 2023
  13. KHORMI I, Al-Iedani O, Alshehri A, Ramadan S, et al
    MR myelin imaging in multiple sclerosis: A scoping review.
    J Neurol Sci. 2023;455:122807.
    >> Share

  14. JAKIMOVSKI D, Kavak KS, Zakalik K, McGraw C, et al
    Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
    J Neurol Sci. 2023;455:122781.
    >> Share

  15. DITTEL LJ, Dittel BN, Brod SA
    Ingested (oral) adrenocorticotropic hormone (ACTH) inhibits interleukin-17 in the central nervous system after adoptive transfer of T helper (Th)1/Th17 T cells in the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis.
    J Neurol Sci. 2023;456:122779.
    >> Share

    October 2023
  16. MIRMOSAYYEB O, Yazdan Panah M, Mokary Y, Ghaffary EM, et al
    Optical coherence tomography (OCT) measurements and disability in multiple sclerosis (MS): A systematic review and meta-analysis.
    J Neurol Sci. 2023;454:120847.
    >> Share

  17. HECHENBERGER S, Helmlinger B, Penner IK, Pirpamer L, et al
    Psychological factors and brain magnetic resonance imaging metrics associated with fatigue in persons with multiple sclerosis.
    J Neurol Sci. 2023;454:120833.
    >> Share

    September 2023
  18. DE LURY AD, Bisulca JA, Lee JS, Altaf MD, et al
    Magnetic resonance imaging detection of deep gray matter iron deposition in multiple sclerosis: A systematic review.
    J Neurol Sci. 2023;453:120816.
    >> Share

  19. MUSTAFA R, Flanagan EP, Duffy DJ, Weinshenker BG, et al
    Laboratory evaluation for the differential diagnosis of possible multiple sclerosis in the United States: A physician survey.
    J Neurol Sci. 2023;453:120781.
    >> Share

    August 2023
  20. OSEN A, Stefoski D, Shoemaker T, Kaplan T, et al
    Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
    J Neurol Sci. 2023;451:120693.
    >> Share

    July 2023
  21. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Corrigendum to "Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis" [Journal of the Neurological Sciences 449C (2023) Start page-End page/JOTNS
    J Neurol Sci. 2023 Jul 17:120695. doi: 10.1016/j.jns.2023.120695.
    >> Share

  22. JEANTIN L, Boudot de la Motte M, Deschamps R, Gueguen A, et al
    Natalizumab extended-interval dosing in a real-life setting.
    J Neurol Sci. 2023;450:120689.
    >> Share

  23. WEBB LM, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS.
    J Neurol Sci. 2023;450:120687.
    >> Share

    May 2023
  24. PATIL SA, Joseph B, Tagliani P, Sastre-Garriga J, et al
    Longitudinal stability of inter-eye differences in optical coherence tomography measures for identifying unilateral optic nerve lesions in multiple sclerosis.
    J Neurol Sci. 2023;449:120669.
    >> Share

    January 2023
  25. KABANOVSKI A, Zaslavsky K, Rotstein D, Margolin E, et al
    A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2023;446:120552.
    >> Share

    December 2022
  26. XIAN C, Barbi C, Goldsworthy MR, Venturelli M, et al
    The interaction between metaplastic neuromodulation and fatigue in multiple sclerosis.
    J Neurol Sci. 2022;444:120521.
    >> Share

  27. ETEMADIFAR M, Abhari AP, Nouri H, Eighani N, et al
    Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
    J Neurol Sci. 2022;444:120518.
    >> Share

    November 2022
  28. ABDELRAZEK MA, Tummala S, Khalid F, Tauhid S, et al
    Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    J Neurol Sci. 2022;444:120501.
    >> Share

    October 2022
  29. SHARMA K, Tolaymat S, Yu H, Elkhooly M, et al
    Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
    J Neurol Sci. 2022;443:120459.
    >> Share

    September 2022
  30. MAHLER JV, Silva GD
    Letter to the editor: Should we stop using post-contrast sequences in the follow-up MRI of patients with multiple sclerosis?
    J Neurol Sci. 2022;442:120421.
    >> Share

  31. GENTILI L, Capuano R, Gaetani L, Fiacca A, et al
    Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents.
    J Neurol Sci. 2022;442:120422.
    >> Share

  32. GROVE CR, Wagner A, Loyd BJ, Dibble LE, et al
    Unique compensatory oculomotor behavior in people living with multiple sclerosis.
    J Neurol Sci. 2022;442:120411.
    >> Share

    August 2022
  33. VISTBAKKA J, Sumelahti ML, Lehtimaki T, Hagman S, et al
    Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study.
    J Neurol Sci. 2022;442:120395.
    >> Share

  34. MERMELSTEIN M, Naftali J, Wilf-Yarkoni A, Lotan I, et al
    Repeated lumbar puncture in search of oligoclonal bands - What is the yield?
    J Neurol Sci. 2022;439:120298.
    >> Share

    July 2022
  35. HARIRCHIAN MH, Zahednasab H, Karampoor S
    The enigmatic role of macrophage inhibitory factor (MIF) in the pathogenesis of multiple sclerosis (MS).
    J Neurol Sci. 2022;440:120351.
    >> Share

  36. HJAERESEN S, Svenningsen AF
    The possible function and regulation of macrophage migration inhibitory factor (MIF) in multiple sclerosis (MS).
    J Neurol Sci. 2022;441:120352.
    >> Share

  37. GENTILI L, Capuano R, Gaetani L, Fiacca A, et al
    Impact of post-contrast MRI in the definition of active multiple sclerosis.
    J Neurol Sci. 2022;440:120338.
    >> Share

    June 2022
  38. HJAERESEN S, Sejbaek T, Axelsson M, Mortensen SK, et al
    MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis.
    J Neurol Sci. 2022;439:120320.
    >> Share

  39. MOCCIA M, Buonomo AR, Scotto R, Viceconte G, et al
    Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series.
    J Neurol Sci. 2022;439:120306.
    >> Share

    May 2022
  40. LOREFICE L, Pilotto S, Fenu G, Cimino P, et al
    Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
    J Neurol Sci. 2022;438:120292.
    >> Share

    February 2022
  41. KATO S, Hagiwara A, Yokoyama K, Andica C, et al
    Microstructural white matter abnormalities in multiple sclerosis and neuromyelitis optica spectrum disorders: Evaluation by advanced diffusion imaging.
    J Neurol Sci. 2022;436:120205.
    >> Share

  42. YOUNG CA, Mills R, Langdon D, Sharrack B, et al
    The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications.
    J Neurol Sci. 2022;436:120188.
    >> Share

    January 2022
  43. DREYER-ALSTER S, Menascu S, Mandel M, Shirbint E, et al
    COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose.
    J Neurol Sci. 2022;434:120155.
    >> Share

  44. CHU L, Casserly C, Rosehart H, Morrow SA, et al
    Is there a multiple sclerosis personality? Personality characteristics in newly diagnosed multiple sclerosis and association with mood and cognition.
    J Neurol Sci. 2022;434:120145.
    >> Share

    November 2021
  45. MENASCU S, Fattal-Valevski A, Vaknin-Dembinsky A, Milo R, et al
    Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage.
    J Neurol Sci. 2021;432:120074.
    >> Share

  46. KENNEY R, Liu M, Patil S, Alroughani R, et al
    Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.
    J Neurol Sci. 2021;430:118067.
    >> Share

    October 2021
  47. BEARD K, Sriwastava S
    Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis.
    J Neurol Sci. 2021;430:120034.
    >> Share

  48. BRINGELAND GH, Blaser N, Myhr KM, Vedeler CA, et al
    Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic.
    J Neurol Sci. 2021;429:117622.
    >> Share

  49. SCOTT TF
    Neurosarcoidosis mimicry of MS: Clues from cases with CNS tissue diagnosis.
    J Neurol Sci. 2021;429:117621.
    >> Share

    September 2021
  50. PLOWMAN RS, Varma H
    Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
    J Neurol Sci. 2021;428:117591.
    >> Share

  51. XIE JS, Jeeva-Patel T, Margolin E
    Balo's concentric sclerosis - A rare entity within the spectrum of demyelinating diseases.
    J Neurol Sci. 2021;428:117570.
    >> Share

  52. CRISTIANO E, Abad P, Becker J, Carra A, et al
    Multiple sclerosis care units in Latin America: Consensus recommendations about its objectives and functioning implementation.
    J Neurol Sci. 2021;429:118072.
    >> Share

    August 2021
  53. RICE DR, Kaplan TB, Hotan GC, Vogel AC, et al
    Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
    J Neurol Sci. 2021;428:117612.
    >> Share

    July 2021
  54. VISSER LA, Huls SPI, Uyl-de Groot CA, de Bekker-Grob EW, et al
    An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
    J Neurol Sci. 2021;428:117587.
    >> Share

    June 2021
  55. VAN DER HIELE K, van Gorp DAM, van Egmond EEA, Jongen PJ, et al
    Self-reported occupational functioning in persons with relapsing-remitting multiple sclerosis: Does personality matter?
    J Neurol Sci. 2021;427:117561.
    >> Share

  56. JAKIMOVSKI D, Zivadinov R, Vaughn CB, Ozel O, et al
    Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis.
    J Neurol Sci. 2021;427:117552.
    >> Share

  57. WIJERATNE T, Grisold W, Carroll W
    World Brain Day 2021 campaign continue to gain the momentum; join us to stop multiple sclerosis.
    J Neurol Sci. 2021;427:117547.
    >> Share

  58. FUJIMORI J, Nakashima I
    Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2021;427:117528.
    >> Share

    May 2021
  59. TAZZA F, Lapucci C, Cellerino M, Boffa G, et al
    Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    J Neurol Sci. 2021;427:117501.
    >> Share

  60. DE MERCANTI SF, Signori A, Cordioli C, Signoriello E, et al
    MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
    J Neurol Sci. 2021;424:117385.
    >> Share

    April 2021
  61. YOUNG CA, Mills R, Rog D, Sharrack B, et al
    Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy.
    J Neurol Sci. 2021;426:117437.
    >> Share

  62. ALLUM JHJ, Rust HM, Lutz N, Schouenborg C, et al
    Characteristics of improvements in balance control using vibro-tactile biofeedback of trunk sway for multiple sclerosis patients.
    J Neurol Sci. 2021;425:117432.
    >> Share

    March 2021
  63. FERRARO D, Annovazzi P, Lanzillo R, Calabrese M, et al
    A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia.
    J Neurol Sci. 2021;424:117430.
    >> Share

    February 2021
  64. EILAM-STOCK T, Shaw MT, Krupp LB, Charvet LE, et al
    Early neuropsychological markers of cognitive involvement in multiple sclerosis.
    J Neurol Sci. 2021;423:117349.
    >> Share

    January 2021
  65. BOSE G, Freedman MS
    Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    J Neurol Sci. 2021;421:117324.
    >> Share

  66. KOVVURU S, Nalleballe K, Onteddu SR, Sharma R, et al
    Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic.
    J Neurol Sci. 2021;420:117230.
    >> Share

    December 2020
  67. WEBER J, Bernsdorff N, Robinson T, Endres D, et al
    Diagnosis of multiple sclerosis in times of MOG and AQP4 autoantibody testing - A monocentric study.
    J Neurol Sci. 2020;421:117289.
    >> Share

    October 2020
  68. VARMA-DOYLE AV, Lukiw WJ, Zhao Y, Lovera J, et al
    A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.
    J Neurol Sci. 2020 Oct 23:117202. doi: 10.1016/j.jns.2020.117202.
    >> Share

  69. BARREIRO-GONZALEZ A, Sanz MT, Carratala-Bosca S, Perez-Miralles F, et al
    Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
    J Neurol Sci. 2020;419:117180.
    >> Share

    September 2020
  70. ILARDI M, Nolan-Kenney R, Fatterpekar G, Hasanaj L, et al
    Role for OCT in detecting hemi-macular ganglion cell layer thinning in patients with multiple sclerosis and related demyelinating diseases.
    J Neurol Sci. 2020;419:117159.
    >> Share

  71. CHAUDHRY F, Bulka H, Rathnam AS, Said OM, et al
    COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    J Neurol Sci. 2020;418:117147.
    >> Share

    July 2020
  72. HUGHES AJ, Patel K, Fitzgerald KC, Brown A, et al
    Reliability and validity of the multiple sclerosis resiliency scale (MSRS).
    J Neurol Sci. 2020;418:116983.
    >> Share

    February 2020
  73. RINI AM, Clerici VT, Rinaldi E, Modesto M, et al
    Severe thrombocytopenia during Natalizumab therapy: A case report.
    J Neurol Sci. 2020;409:116587.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016